Miller Anestesia

activity in subjects with the genotypically normal

enzyme. Anesthesiology 53:517–520, 1980.

32. Gissen AJ, Katz RL, Karis JH, Papper EM: Neuro-

muscular block in man during prolonged arterial

infusion with succinylcholine. Anesthesiology

27:242–249, 1966.

33. Torda TA, Graham GG, Warwick NR, Donohue P:

Pharmacokinetics and pharmacodynamics of suxa-

methonium. Anaesth Intensive Care 25:272–278,

1997.

34. Birch JH, Foldes FF, Rendell-Baker L: Causes and

prevention of prolonged apnea with succinylcho-

line. Anesth Analg 35:609–633, 1956.

35. Lepage L, Schiele F, Gueguen R, Siest G: Total cho-

linesterase in plasma: Biological variations and refe-

rence limits. Clin Chem 31:546–550, 1985.

36. Sunew KY, Hicks RG: Effects of neostigmine and

pyridostigmine on duration of succinylcholine

action and pseudocholinesterase activity. Anesthe-

siology 49:188–191, 1978.

37. Lindsay PA, Lumley J: Suxamethonium apnoea

masked by tetrahydroaminacrine. Anaesthesia

33:620–622, 1978.

38. Kao YJ, Tellez J, Turner DR: Dose-dependent effect

of metoclopramide on cholinesterases and suxame-

thonium metabolism. Br J Anaesth 65:220–224,

1990.

39. Woodworth GE, Sears DH, Grove TM, et al: The

effect of cimetidine and ranitidine on the duration

of action of succinylcholine. Anesth Analg 68:295–

297, 1989.

40. Fisher DM, Caldwell JE, Sharma M, Wiren JE: The

influence of bambuterol (carbamylated terbutaline)

on the duration of action of succinylcholine-indu-

ced paralysis in humans. Anesthesiology 69:757–

759, 1988.

41. Barabas E, Zsigmond EK, Kirkpatrick AF: The inhi-

bitory effect of esmolol on human plasmacholines-

terase. Can Anaesth Soc J 33:332–335, 1986.

42. Pantuck EJ: Ecothiopate iodide eye drops and pro-

longed response to suxamethonium. Br J Anaesth

38:406–407, 1966.

43. Kalow W, Genest K: A method for the detection of

atypical forms of human serum cholinesterase;

determination of dibucaine numbers. Can J

Biochem 35:339–346, 1957.

44. Jensen FS, Viby-Mogensen J: Plasma cholinesterase

and abnormal reaction to succinylcholine: Twenty

years’ experience with the Danish Cholinesterase

Research Unit. Acta Anaesthesiol Scand 39:150–

156, 1995.

45. Primo-Parmo SL, Lightstone H, La Du BN: Charac-

terization of an unstable variant (BChE115D) of

human butyrylcholinesterase. Pharmacogenetics

7:27–34, 1997.

46. Galindo AHF, Davis TB: Succinylcholine and

cardiac excitability. Anesthesiology 23:32–40, 1962.

47. Goat VA, Feldman SA: The dual action of suxame-

thonium on the isolated rabbit heart. Anaesthesia

27:149–153, 1972.

48. Jonsson M, Dabrowski M, Gurley DA, et al: Activa-

tion and inhibition of human muscular and neuronal

nicotinic acetylcholine receptors by succinylcholine.

Anesthesiology 104:724–733, 2006.

49. Stoelting RK, Peterson C: Heart-rate slowing and

junctional rhythm following intravenous succinyl-

choline with and without intramuscular atropine

preanesthetic medication. Anesth Analg 54:705–

709, 1975.

50. Schoenstadt DA,Whitcher CE: Observations on the

mechanism of succinylcholine-induced cardiac arr-

hythmias. Anesthesiology 24:358–363, 1963.

51. Leiman BC, Katz J, Butler BD: Mechanisms of suc-

cinylcholine-induced arrhythmias in hypoxic or

hypoxic:hypercarbic

dogs. Anesth Analg 66:1292–

1297, 1987.

52. Derbyshire DR: Succinylcholine-induced increases

in plasma catecholamine levels in humans. Anesth

Analg 63:465–467, 1984.

53. Powell JN, Golby M: The pattern of potassium libe-

ration following a single dose of suxamethonium in

normal and uraemic rats. Br J Anaesth 43:662–668,

1971.

54. Walton JD, Farman JV: Suxamethonium hyperka-

laemia in uraemic neuropathy.Anaesthesia 28:666–

668, 1973.

55. Schwartz DE, Kelly B, Caldwell JE, et al: Succinyl-

choline-induced hyperkalemic arrest in a patient

with severe metabolic acidosis and exsanguinating

hemorrhage. Anesth Analg 75:291–293, 1992.

56. Antognini JF, Gronert GA: Succinylcholine causes

profound hyperkalemia in hemorrhagic, acidotic

rabbits. Anesth Analg 77:585–588, 1993.

57. Antognini JF: Splanchnic release of potassium after

hemorrhage and succinylcholine in rabbits. Anesth

Analg 78:687–690, 1994.

58. Kohlschütter B, Baur H, Roth F: Suxamethonium-

induced hyperkalaemia in patients with severe

intra-abdominal infections. Br J Anaesth 48:557–

562, 1976.

59. Stevenson PH, Birch AA: Succinylcholine-induced

hyperkalemia in a patient with a closed head injury.

Anesthesiology 51:89–90, 1979.

60. Birch AA Jr, Mitchell GD, Playford GA, Lang CA:

Changes in serum potassium response to succinyl-

choline following trauma. JAMA 210:490–493,

1969.

61. Martyn JA, Richtsfeld M: Succinylcholine-induced

hyperkalemia in acquired pathologic states: Etiolo-

gic factors and molecular mechanisms. Anesthesio-

logy 104:158–169, 2006.

62. Pandey K, Badola RP, Kumar S: Time course of

intraocular hypertension produced by suxametho-

nium. Br J Anaesth 44:191–196, 1972.

63. Indu B, Batra YK, Puri GD, Singh H: Nifedipine

attenuates the intraocular pressure response to intu-

bation following succinylcholine. Can J Anaesth

36:269–272, 1989.

64. Meyers EF, Krupin T, Johnson M, Zink H: Failure of

nondepolarizing neuromuscular blockers to inhibit

succinylcholine-induced increased intraocular

pressure,a controlled study.Anesthesiology 48:149–

151, 1978.

65. Miller RD, Way WL, Hickey RF: Inhibition of suc-

cinylcholine-induced increased intraocular pres-

sure by non-depolarizing muscle relaxants.

Anesthesiology 29:123–126, 1968.

66. Libonati MM, Leahy JJ, Ellison N: The use of suc-

cinylcholine in open eye surgery. Anesthesiology

62:637–640, 1985.

67. Grennan J: The cardio-oesophageal junction. Br J

Anaesth 33:432, 1961.

68. Miller RD, Way WL: Inhibition of succinylcholine-

induced increased intragastric pressure by nonde-

polarizing muscle relaxants and lidocaine.

Anesthesiology 34:185–188, 1971.

69. Salem MR,Wong AY, Lin YH: The effect of suxame-

thonium on the intragastric pressure in infants and

children. Br J Anaesth 44:166–170, 1972.

70. Minton MD, Grosslight K, Stirt JA, Bedford RF:

Increases in intracranial pressure from succinylcho-

line. Prevention by prior nondepolarizing blockade.

Anesthesiology 65:165–169, 1986.

71. Brodsky JB, Brock-Utne JG, Samuels SI: Pancuro-

nium pretreatment and post-succinylcholine myal-

gias. Anesthesiology 51:259–261, 1979.

72. Waters DJ, Mapleson WW: Suxamethonium pains:

Hypothesis and observation. Anaesthesia 26:127–

141, 1971.

73. McLoughlin C, Elliott P, McCarthy G, Mirakhur

RK: Muscle pains and biochemical changes

following suxamethonium administration after six

pretreatment regimens. Anaesthesia 47:202–206,

1992.

74. Naguib M, Farag H, Magbagbeola JA: Effect of pre-

treatment with lysine acetyl salicylate on suxame-

thonium-inducedmyalgia.Br JAnaesth 59:606–610,

1987.

75. Smith I, Ding Y,White PF: Muscle pain after outpa-

tient laparoscopy—influence of propofol versus

thiopental and enflurane. Anesth Analg 76:1181–

1184, 1993.

76. Leary NP, Ellis FR: Masseteric muscle spasm as a

normal response to suxamethonium. Br J Anaesth

64:488–492, 1990.

77. Meakin G,Walker RW, Dearlove OR: Myotonic and

neuromuscular blocking effects of increased doses

of suxamethonium in infants and children. Br J

Anaesth 65:816–818, 1990.

78. Van der Spek AF, Fang WB, Ashton-Miller JA, et al:

The effects of succinylcholine on mouth opening.

Anesthesiology 67:459–465, 1987.

79. Littleford JA, Patel LR, Bose D, et al: Masseter

muscle spasm in children: Implications of conti-

nuing the triggering anesthetic. Anesth Analg

72:151–160, 1991.

80. Clarke RSJ: Intubating conditions and neuromus-

cular effects following vecuronium bromide. Com-

parison with suxamethonium chloride and

pancuronium bromide. Clinical Experiences with

Norcuron. Amsterdam, Excerpta Medica, 1983.

81. Naguib M, Samarkandi A, Riad W, Alharby SW:

Optimal dose of succinylcholine revisited.Anesthe-

siology 99:1045–1049, 2003.

82. Naguib M, Samarkandi AH, Abdullah K, et al: Suc-

cinylcholine dosage and apnea-induced hemoglo-

bin desaturation in patients. Anesthesiology

102:35–40, 2005.

83. Miller RD: The advantages of giving

-tubocurarine

before succinylcholine. Anesthesiology 37:568–569,

1972.

84. Donati F, Gill SS, Bevan DR, et al: Pharmacokinetics

and pharmacodynamics of atracurium with and

without previous suxamethonium administration.

Br J Anaesth 66:557–561, 1991.

85. Dubois MY, Lea DE, Kataria B, et al: Pharmacody-

namics of rocuronium with and without prior

administration of succinylcholine. J Clin Anesth

7:44–48, 1995.

86. Naguib M, Abdulatif M, Selim M, al-Ghamdi A:

Dose-response studies of the interaction between

mivacurium and suxamethonium. Br J Anaesth

74:26–30, 1995.

87. Erkola O, Rautoma P, Meretoja OA: Interaction

between mivacurium and succinylcholine. Anesth

Analg 80:534–537, 1995.

88. Lee C, Katz RL: Neuromuscular pharmacology. A

clinical update and commentary. Br J Anaesth

52:173–188, 1980.

89. Ramsey FM, Lebowitz PW, Savarese JJ, Ali HH: Cli-

nical characteristics of long-term succinylcholine

neuromuscular blockade during balanced anesthe-

sia. Anesth Analg 59:110–116, 1980.

90. Lee C: Structure, conformation, and action of neu-

romuscular blocking drugs. Br J Anaesth 87:755–

769, 2001.

91. Everett AJ, Lowe LA, Wilkinson S: Revision of the

structures of (+)-tubocurarine chloride and

(+)-chondocurine. J Chem Soc D 13:1020–1021,

1970.

92. Waser PG: Chemistry and pharmacology of natural

curare compounds, Neuromuscular blocking and

stimulating agents.

Cheymol J (ed): International

Encyclopedia of Pharmacology and Therapeutics.

Oxford, Pergamon Press, 1972, pp 205–239.

93. Hill SA, Scott RPF, Savarese JJ: Structure-activity

relationships: From tubocurarine to the present day.

Baillieres Clin Anesthesiol 8:317–348, 1994.

94. Stenlake JB, Waigh RD, Dewar GH, et al: Biode-

gradable neuromuscular blocking agents. 6. Ste-

reochemical studies on atracurium and related

polyalkylene di-esters. Eur J Med Chem 19:441–

450, 1984.

95. Wastila WB, Maehr RB, Turner GL, et al: Compara-

tive pharmacology of cisatracurium (51W89), atra-

curium, and five isomers in cats. Anesthesiology

85:169–177, 1996.

670

Farmacología y anestesia